Please login to the form below

Not currently logged in
Email:
Password:

Stuart Collinson joins Silence Therapeutics

He replaces Simon Sturge as non-executive director

Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

The move follows Simon Sturge's resignation as non-executive director of the biotechnology company as he seeks to focus on his other business commitments.

Dr Collinson has held senior management roles in public and private life science companies across Europe and the US, including at GlaxoWellcome, now GlaxoSmithKline, Baxter International and Cabrellis Pharmaceuticals, now part of Celgene.

He is a partner of US-based VC firm Forward Ventures and currently also serves as chairman and chief executive officer of Tioga Pharmaceuticals and director for both Arcturus Therapeutics and Essentialis.

Chief executive officer of Silence Therapeutics Ali Mortazavi said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

21st January 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics